Acral melanomas occur on the palms, soles of the feet, or underneath the fingernails. Mucosal melanomas arise in the mouth, sinuses, rectum, vulva, or vagina. The purpose of this study is to evaluate the safety and effectiveness of a drug called dasatinib in patients with acral, vulvovaginal, or other mucosal melanoma that is locally advanced and cannot be surgically removed, or has spread to other parts of the body.
Dasatinib is approved for treating a form of leukemia, but its use in melanoma is considered investigational. It works against cancer by targeting a mutated form of a protein called c-KIT, which drives cancer growth. Dasatinib is taken orally (by mouth).